Literature DB >> 22033885

[Thrombophilic states in intensive care medicine].

L Engelmann1.   

Abstract

Thrombophilic states are common in intensive care medicine. Generally, they are complications of serious underlying diseases or adverse effects of treatment measures. The attributive mortality rate for thrombophilic states is high. Early recognition and management are, thus, indispensable. In this review, important diagnostic and therapeutic aspects are briefly summarized. Leading symptoms and the context to the underlying disease or therapy, which result in a thrombophilic state, are the basics for a specific diagnostic workup. Almost all current treatment recommendations are based on expert opinion.

Mesh:

Year:  2011        PMID: 22033885     DOI: 10.1007/s00063-011-0015-8

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  36 in total

1.  Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.

Authors:  F B Taylor; C H Toh; W K Hoots; H Wada; M Levi
Journal:  Thromb Haemost       Date:  2001-11       Impact factor: 5.249

2.  Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias.

Authors:  Sarah L Allford; Beverley J Hunt; Peter Rose; Samuel J Machin
Journal:  Br J Haematol       Date:  2003-02       Impact factor: 6.998

3.  Eculizumab for atypical hemolytic-uremic syndrome.

Authors:  Jens Nürnberger; Thomas Philipp; Oliver Witzke; Anabelle Opazo Saez; Udo Vester; Hideo Andreas Baba; Andreas Kribben; Lothar Bernd Zimmerhackl; Andreas R Janecke; Mato Nagel; Michael Kirschfink
Journal:  N Engl J Med       Date:  2009-01-29       Impact factor: 91.245

Review 4.  Atypical hemolytic-uremic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

5.  Eculizumab in severe Shiga-toxin-associated HUS.

Authors:  Anne-Laure Lapeyraque; Michal Malina; Véronique Fremeaux-Bacchi; Tobias Boppel; Michael Kirschfink; Mehdi Oualha; François Proulx; Marie-José Clermont; Françoise Le Deist; Patrick Niaudet; Franz Schaefer
Journal:  N Engl J Med       Date:  2011-05-25       Impact factor: 91.245

Review 6.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.

Authors:  Phillip I Tarr; Carrie A Gordon; Wayne L Chandler
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

7.  Hemolytic Uremic Syndrome After an Escherichia coli O111 Outbreak.

Authors:  Emily W Piercefield; Kristy K Bradley; Rebecca L Coffman; Sue M Mallonee
Journal:  Arch Intern Med       Date:  2010-10-11

8.  Dexamethasone treatment does not improve the outcome of women with HELLP syndrome: a double-blind, placebo-controlled, randomized clinical trial.

Authors:  Javier E Fonseca; Fabián Méndez; Claudia Cataño; Fernando Arias
Journal:  Am J Obstet Gynecol       Date:  2005-11       Impact factor: 8.661

9.  Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura.

Authors:  Pavan S Reddy; Delva Deauna-Limayo; James D Cook; Siddhartha S Ganguly; Carol Blecke; David C Bodensteiner; Barry S Skikne; Mervin A Sahud
Journal:  Ann Hematol       Date:  2004-10-29       Impact factor: 3.673

10.  Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders.

Authors:  James N George; Robert D Woodson; Joseph E Kiss; Kiarash Kojouri; Sara K Vesely
Journal:  J Clin Apher       Date:  2006-04       Impact factor: 2.821

View more
  1 in total

Review 1.  Prethrombotic, prothrombotic, thrombophilic states, hypercoagulable state, thrombophilia etc.: semantics should be respected even in medical papers.

Authors:  A Girolami; E Cosi; S Ferrari; A M Lombardi; B Girolami
Journal:  J Thromb Thrombolysis       Date:  2017-04       Impact factor: 2.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.